NovaMeds
Evidence-based guides to medicines, active ingredients and emerging research.
When losing significant weight on GLP-1 medicines, between 20% and 40% of total mass lost is lean tissue. We examine clinical trial DEXA findings and evidence-based protocols to preserve skeletal muscle.
CagriSema combines the long-acting amylin analog cagrilintide with semaglutide. Here is what Phase 3 REDEFINE 1 trial data demonstrate regarding its dual mechanism, 22.7% weight loss efficacy and current FDA NDA review.
Approved by the US FDA on April 1, 2026 as Foundayo for chronic weight management, orforglipron is the first daily non-peptide oral GLP-1 receptor agonist taken without food or water restrictions. We examine its Phase 3 trial data, mechanisms and regulatory status.
Mysimba combines naltrexone and bupropion to target hypothalamic hunger and mesolimbic reward circuits. Here is the evidence on its mechanism, weight loss outcomes from the COR trials, titration and contraindications.
Metformin is the global first-line foundation for type 2 diabetes. We examine what clinical trials, including the 15-year Diabetes Prevention Program, prove regarding its modest, sustainable weight-loss effects and metabolic benefits.
Bremelanotide (PT-141) is a synthetic cyclic heptapeptide that acts centrally on hypothalamic melanocortin receptors to stimulate sexual desire. Here is what FDA approval data, the RECONNECT trials and research literature demonstrate.
Rapamycin is the most robust pharmacological lifespan-extending compound in preclinical biology. We examine how mTOR inhibition works, the NIA Interventions Testing Program data, human trial evidence and safety risks.
Nicotinamide adenine dinucleotide (NAD+) declines with age. We evaluate the cellular biology of the NAD+ salvage pathway, comparing oral precursors (NR, NMN) to intravenous infusions and reviewing human evidence.
TB-500 is a synthetic peptide based on the active domain of Thymosin Beta-4. We examine how actin sequestration regulates cell migration, preclinical tissue repair data, anti-doping bans and research status.
GHK-Cu is a naturally occurring copper-binding tripeptide that regulates extracellular matrix remodelling and gene expression. We review the evidence behind its collagen-stimulating, wound-healing and dermatological properties.
Retatrutide is an investigational GIP, GLP-1 and glucagon receptor agonist. What the trials show, what remains unknown, and why it is not an approved medicine.
BPC-157 is an unapproved research peptide. We separate animal, laboratory and human evidence from online claims and explain its FDA, UK and anti-doping status.